MedTrace Logo

A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer

NCT00123318 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2013-06-18

No results posted yet for this study

Summary

The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with radiotherapy.

Conditions

Interventions

DRUG

epirubicin

50mg/m2 IV day 1

DRUG

cisplatin

60mg/m2 IV day 1

DRUG

5-fluorouracil

5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line

RADIATION

Radiotherapy

45Gy 25 Fractions, 5 days/week for 5 weeks

Sponsors & Collaborators

  • The Royal Australian and New Zealand College of Radiologists

    collaborator OTHER

  • Trans Tasman Radiation Oncology Group

    lead OTHER

Principal Investigators

  • Trevor Leong · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123318 on ClinicalTrials.gov